Posttransplantation chronic renal damage in nonrenal transplant recipients

Kidney International

Volumn 68, Issue 4, 2005, Pages 1453-1463

  Stratta, Piero ^a   Canavese, Caterina ^b   Quaglia, Marco ^b   Balzola, Federico ^b   Bobbio, Marco ^b   Busca, Alessandro ^b   Franchello, Alessandro ^b   Libertucci, Daniela ^b   Mazzucco, Gianna ^b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b NONE

Author keywords

Calcineurin inhibitors; Calcineurin inhibitors sparing protocols; End stage renal disease; Nephrotoxicity; Nonrenal transplantation

Indexed keywords

ACETYLCHOLINE; AMINO ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; AZATHIOPRINE; BASILIXIMAB; BUDESONIDE; CALCINEURIN INHIBITOR; CANDESARTAN HEXETIL; CYCLOSPORIN A; DACLIZUMAB; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; HYPERTENSIVE FACTOR; IMMUNOSUPPRESSIVE AGENT; IODOHIPPURATE SODIUM I 131; IOTALAMIC ACID I 125; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITROPRUSSIDE SODIUM; PENTOXIFYLLINE; RAPAMYCIN; SACROLIMUS; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ARTICLE; CARDIAC GRAFT REJECTION; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIALYSIS; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERKALEMIA; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; INCIDENCE; INTESTINE TRANSPLANTATION; INTRAOPERATIVE PERIOD; KIDNEY ALLOGRAFT; KIDNEY AMYLOIDOSIS; KIDNEY CALCIFICATION; KIDNEY DISTAL TUBULE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY INTERSTITIUM; KIDNEY TUBULE ACIDOSIS; KIDNEY TUBULE DISORDER; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG GRAFT REJECTION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT; RENOVASCULAR DISEASE; RISK FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINE;

HUMANS; INCIDENCE; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 31644439038     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00558.x     Document Type: Article

References (95)

1. PATTISON JM, PETERSEN J, KUO P, et al: The incidence of renal failure in one hundred consecutive heart-lung transplant recipients. Am J Kidney Dis 26:643-648, 1995
2. WILKINSON AH, COHEN DJ: Renal failure in the recipients of nonrenal solid organ transplants. J Am Soc Nephrol 10:1136-1144, 1999
3. BROEKROELOFS J, STEGEMAN CA, NAVIS G, DE JONG PE: Prevention of renal function loss after nonrenal solid organ transplantation-how can nephrologists help to keep the kidneys out of the line of fire? Nephrol Dial Transplant 14:1841-1843, 1999
4. OJO AO, HELD PJ, PORT FK, et al: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349:931-940, 2003
5. MAGEE C, PASCUAL M: The growing problem of chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349:994-996, 2003
6. NAUMANN U, BECHSTEIN WO, KAHL A, et al: Acute and chronic renal failure after liver transplantation: Prevalence, incidence, risk factors and prognosis. Transplantations Medizin 3:133, 1995
7. FISHER NC, NIGHTINGALE PG, GUNSON BK, et al: Chronic renal failure following liver transplantation: A retrospective analysis. Transplantation 66:59-66, 1998
8. GONWA TA, MAI ML, MELTON LB, et al: End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 72:1934-1939, 2001
9. LYNN M, ABREO K, ZIBARI G, MCDONALD J: End-stage renal disease in liver transplants. Clin Transplant 15:66-69, 2001
10. COHEN AJ, STEGALL MD, ROSEN CB, et al: Chronic renal dysfunction late after liver transplantation. Liver Transplant 8:922-924, 2002
11. PAWARODE A, FINE DM, THULUVATH PJ: Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transplant 9:741-747, 2003
12. MORENO JM, CUERVAS-MONS V, RUBIO E, et al: Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transplant Proc 35:1907-1908, 2003
13. GREENBERG A, THOMPSON ME, GRIFFITH BJ: Cyclosporine nephrotoxicity in cardiac allograft patients - A seven year follow-up. Tranplantation 50:589-593, 1990
14. LEWIS RM, VAN BUREN CT, RADOVANCEVIC B, et al: Impact of long-term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts: Serial renal function in heart and kidney transplant recipients. J Heart Lung Transplant 10:63-70, 1991
15. GONWA TA, MAI ML, PILCHER J, et al: Stability of long-term renal function in heart transplant patients treated with induction therapy and low-dose cyclosporine. J Heart Lung Transplant 11:926-928, 1992
16. ZIETSE R, BALK AH, VD DORPEL MA, et al: Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 14:1-5, 1994
17. TINAWI M, MILLER L, BASTANI B: Renal function in cardiac transplant recipients: Retrospective analysis of 133 consecutive patients in a single center. Clin Transplant 11:1-8, 1997
18. GORAL S, YNARES C, SHYR Y, et al: Long-term renal function in heart transplant recipients receiving cyclosporine therapy. J Heart Lung Transplant 16:1106-1112, 1997
19. GOLDSTEIN DJ, ZUECH N, SEHGAL V, et al: Cyclosporin-associated end-stage renal disease after cardiac transplantation: Incidence and progression. Transplantation 63:664-668, 1997
20. VAN GELDER T, AGGIE HMMB, ZIETSE R, et al: Renal insufficiency after heart transplantation: A case-control study. Nephrol Dial Transplant 13:2322-2326, 1998
21. LINDELOW B, BERGH CH, HERLITZ H, WAAGSTEIN F: Predictors and evolution of renal function during nine years following heart transplantation. J Am Soc Nephrol 11:951-957, 2000
22. SATCHITHANANDA DK, PARAMESHWAR J, SHARPLES L, et al: The incidence of end-stage renal failure in 17 years of heart transplantation: A single center experience. J Heart Lung Transplant 21:651-657, 2002
23. GARRIDO IP, CRESPO-LEIRO MG, PANIAGUA MJ, et al: Renal dysfunction after orthotopic heart transplantation: Incidence, natural history, and risk factors. Transplant Proc 35:2014-2016, 2003
24. RUBEL JR, MILFORD EL, MCKAY DB, JARCHO JA: Renal insufficiency and end-stage renal disease in the heart transplant population. J Heart Lung Transplant 23:289-300, 2004
25. TSIMARATOS M, VIARD L, KREITMANN B, et al: Kidney function in cyclosporine-treated paediatric pulmonary transplant recipients. Transplantation 69:2055-2059, 2000
26. MYERS BD, NEWTON L: Cyclosporin-induced chronic nephropathy: An obliterative microvascular renal injury. J Am Soc Nephrol 2:S45-S52, 1991
27. GRIFfiTHS MH, CROWE AV, PAPADAKI L, et al: Cyclosporin nephrotoxicity in heart and lung transplant patients. QJM 89:751-763, 1996
28. OGITA K, TAKADA N, TAGUCHI T, et al: Renal tubular acidosis secondary to FK506 in living donor liver transplantation: A case report. Asian J Surg 26:218-220, 2003
29. SCHWIMMER J, NADASDY TA, SPITALNIK PF, et al: De novo thrombotic microangiopathy in renal transplant recipients: A comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 41:471-479, 2003
30. LAPOINTE M, BAILLIE GM, BHASKAR SS, et al: Cyclosporine-induced hemolytic uremic syndrome and hemorrhagic colitis following renal transplantation. Clin Transplant 13:526-530, 1999
31. JANKAUSKIENE A, DRUSKIS V, LAURINAVICIUS A: Cyclosporine nephrotoxicity: Associated allograft dysfunction at low trough concentration. Clin Nephrol 56:27-29, 2001
32. OKA K, MORIYAMA T, IMAI E, et al: A case of tacrolimus nephrotoxicity appearing in a second renal transplantation patient. Clin Transplant 15:30-34, 2001
33. DAVIES DR, BRITMANN I, PARDO J: Histopatology of calcineurin inhibitor-induced nephrotoxicity. Transplantation 69 (Suppl 12):S11-S13, 2000
34. MIAHATSCH MJ, RYFFEL B, GUDAT F: The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int 48:63-69, 1995
35. HEYDENDAEL VM, SPULS PI, TEN BERGE IJ, et al: Cyclosporin trough levels: Is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels. Br J Dermatol 147:122-129, 2002
36. DISCHE FE, NEUBERGER J, KEATING J, et al: Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A. Lab Invest 58:395-402, 1988
37. CRAWFORD DH, ENDRE ZH, AXELSEN RA, et al: Universal occurrence of glomerular abnormalities in patients receiving liver transplants. Am J Kidney Dis 19:339-344, 1992
38. LYNN M, ABREO K, ZIBARI G, MCDONALD J: End-stage renal disease in liver transplants. Clin Transplant 15 (Suppl 6):66-69, 2001
39. BERTANI T, FERRAZZI P, SCHIEPPATI A: Nature and extent of glomerular injury induced by cyclosporin in heart transplant patients. Kidney Int 40:243-250, 1991
40. NIZZE H, MIHATSCH MJ, ZOLLINGER HU, et al: Cyclosporine-associated nephropathy in patients with heart and bone marrow transplants. Clin Nephrol 30:248-260, 1988
41. ZIETSE R, BALK AH, VD DORPEL M, et al: Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 14:1-5, 1994
42. FALKENHAIN ME, COSIO FG, SEDMAK DD: Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation 15:364-370, 1996
43. ZALTZMAN JS, PEI Y, MAURER J, et al: Cyclosporine nephrotoxicity in lung transplant recipients. Transplantation 54:875-878, 1992
44. PALLER MS, CAHILL B, HARMON KR, et al: Glomerular disease and lung transplantation. Am J Kidney Dis 26:527-531, 1995
45. COHEN DJ, LOERTSCHER R, RUBIN M: Cyclosporine: A new immunosuppressive agent for transplantation. Ann Intern Med 101:667-682, 1984
46. MYERS BD, NEWTON L, BOSHKOS C. Chronic injury of human renal microvessels with low-dose cyclosporine therapy. Transplantation 46:694-703, 1988
47. CAMPISTOL JM, SACKS SH: Mechanism of nephrotoxicity. Transplantation 69 (Suppl 12):S5-S10: 2000
48. REMUZZI G, PERICO N: Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int 52:S70-S74, 1995
49. PAUL LC: Chronic renal transplant loss. Kidney Int 47:1491-1499, 1995
50. LEWIS RM, VAN BUREN CT, RADOVANCEVIC B, et al: Impact of long-term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts: Serial renal function in heart and kidney transplant recipients. J Heart Lung Transplant 10:63-70, 1991
51. ABRASS CK, BERfiELD AK, STEHMAN-BREEN C, et al: Unique changes in interstitial extracellular martix composition are associated with rejection and cyclosporin toxicity in human renal allograft biopsies. Am J Kidney Dis 33:11-20, 1999
52. BAID S, COSIMI AS, TOLKOFF-RUBIN N, et al: Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation 70:255-261, 2000
53. BROEKROELOFS J, NAVIS GJ, STEGEMAN CA: Lung transplantation. Lancet 351:1064, 1998
54. BAAN CC, BALK AH, HOLWEG CT, et al: Renal failure after clinical heart transplantation is associated with the TGF-beta 1 codon 10 gene polymorphism. J Heart Lung Transplant 19:866-872, 2000
55. JAHANSOUZ F, KRIETT JM, SMITH CM, et al: Potentiation of cyclosporine nephrotoxicity by nafcillin in lung transplant recipients. Transplantation 55:1045-1048, 1993
56. CHAN C, MAURER L, CARDELLA C, et al: A randomized controlled trial of verapamil on cycloporine nephrotoxicity in heart and lung transplant recipients. Transplantation 63:1435-1440, 1997
57. BURDMANN EA, ANDOH T, NAST CC: Prevention of experimental cyclosporine-induced interstitial fibrosis by losartan and enalapril. Kidney Int 269:491-499, 1995
58. KON V, HUNLEY TE, FOGO A: Combined antagonism of endothelin A/B receptors linkes endothelin to vasoconstriction whereas angiotensin II affects fibrosis. Studies in chronic cyclosporine nephrotoxicity in rats. Transplantation 60:89-95, 1995
59. LASSILA M, FINCKENBERG P, PERE AK, et al: Enalapril and valsartan improve cyclosporine A-induced vascular dysfunction in spontaneously hypertensive rats. Eur J Pharmacol 398:99-106, 2000
60. PADI SS, CHOPRA K: Selective angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity. Pharmacol Res 45:413-420, 2002
61. FLECHNER SM: Minimizing calcineurin inhibitor drugs in renal transplantation. Transplant Proc 35 (Suppl 3A):S118-S121, 2003
62. OLYAEI AJ, DE MATTOS AM, BENNET WM: Nephrotoxicity of immunosuppressive drugs: New insight and preventive drugs. Curr Opin Crit Care 7:384-389, 2001
63. PESCOVITZ MD, GOVANI M: Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients. Am J Kidney Dis 38 (Suppl 2):S16-S21, 2001
64. JOHNSON RWG, KREIS H, OBERBAUER R, et al: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72:777-786, 2001
65. OJO AO, MEIER-KRIESCHE HU, HANSON JA, et al: Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69:2405-2409, 2000
66. MORELON E, KREIS H: Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 35 (Suppl 3):S52-S57, 2003
67. SHIHAB FS, BENNETT WM, YI H, et al: Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity. Am J Transplant 3:1550-1559, 2003
68. STALLONE G, DI PAOLO S, SCHENA A, et al: Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 15:998-1003, 2003
69. VINCENTI F, RAMOS E, BRATTSTROM C, et al: Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 15:1282-1287, 2001
70. KNECHTLE SJ, PIRSCH JD, FECHNER HJ JR., et al: Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 3:722-730, 2003
71. GROTH CG, BACKMAN L, MORALES JM, et al: Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 15:1036-1042, 1999
72. KREIS H, CISTERNE JM, LAND W, et al: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 15:1252-1260, 2000
73. FLECHNER SM, GOLDFARB D, MODLIN C, et al: Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 27:1070-1076, 2002
74. HARIHARAN S, MCBRIDE MA, COHEN EP: Evolution of endpoints for renal transplant outcome. Am J Transplant 3:933-941, 2003
75. PLATZ KP, MUELLER AR, BLUMHARDT G, et al: Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients. Transplant Int 7:S52-S73, 1994
76. MOR E, PATEL T, GLABMAN S, et al: Comparison of short and long-term renal function in liver transplant patients receiving cyclosporin or FK 506. Transplant Int 7 (Suppl 1):S77-S80, 1994
77. ENGLISH RF, POPHAL SA, BACANU SA, et al: Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. Am J Transplant 2:769-773, 2002
78. KLOMPMAKER IJ, HOMAN VAN DER HEIDE JJ, TEGZESS AM, et al: Effects of cyclosporin A withdrawal on renal function and renal stimulation in liver transplant patients treated with triple-drug immunosuppression for over 2 years. Nephrol Dial Transplant 9:1629-1633, 1994
79. COTTERELL AH, FISHER RA, KING AL, et al: Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 16 (Suppl 7):S49-S51, 2002
80. NAIR S, EASON J, LOSS G: Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transplant 9:126-129, 2003
81. NEFF GW, MONTALBANO M, SLAPAK-GREEN G, et al: Sirolimus therapy in orthtopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. Transplant Proc 35:3029-3031, 2003
82. ZIOLKOWSKI J, PACZEK L, SENATORSKI G, et al: Renal function after liver transplantation: calcineurin inhibitor related nephrotoxicity. Transplant Proc 35:2307-2309, 2003
83. MACDONALD AS: Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. Transplant Proc 35 (Suppl 3):S201-S208, 2003
84. CANTAROVICH M, TZIMAS GN, BARKUN J: Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation 76:98-102, 2003
85. MORENO JM, RUBIO E, PONS F, et al: Usefulness of mycophenolate mofetil in patients with chronic renal insufficiency after liver transplantation. Transplant Proc 35:715-717, 2003
86. PFITZMANN R, KLUPP J, LANGREHR JM, et al: Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation 15:130-136, 2003
87. BUNKE M, SLOAN R, BRIER M, et al: An improved glomerular filtration rate in cardiac transplant recipients with once-a-day cyclosporine dosing. Transplantation 59:537-540, 1995
88. WHITE JR JR., ROCKWOOD T, WILSON D, et al: The effects of pentoxifylline on the prevention of cyclosporine-induced nephrotoxicity in cardiac transplant patients. Clin Ther 16:673-679, 1994
89. TEDORIYA T, KEOGH AM, KUSANO K, et al: Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil. J Heart Lung Transplant 21:976-982, 2002
90. ALEKSIC I, BARYALEI M, BUSCH T, et al: Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation 69:1586-1590, 2000
91. GROETZNER J, MEISER BM, SCHIRMER J, et al: Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: Which treatment reveals more side effects during long-term follow-up? Transplant Proc 33:1461-1464, 2001
92. ISRANI A, BROZENA S, PANKEWYCZ O, et al: Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients. Am J Kidney Dis 39:16, 2002
93. SOCCAL PM, GASCHE Y, FAVRE H, et al: Improvement of drug-induced chronic renal failure in lung transplantation. Transplantation 15:164-165, 1999
94. SNELL GI, LEVVEY BJ, CHIN W, et al: Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 21:540-546, 2002
95. ALLERS C, EICHHORN J, LECKEL K, et al: Tacrolimus, daclizumab, sirolimus and budesonide after small bowel transplantation in order to reduce nephrotoxicity. Transplant Proc 34:942, 2002